Amorfix to present at workshop for vCJD diagnostic assays hosted by the European Commission



    TSX: AMF

    TORONTO, Sept. 20 /CNW/ - Amorfix Life Sciences (TSX: AMF), a company
focused on diagnostics and treatments for brain-wasting diseases, today
announced that it has been invited to present at a workshop on the common
technical specifications (CTS) for variant Creutzfeldt-Jacob Disease (vCJD)
diagnostic assays to be held on October 26 in Brussels, Belgium and sponsored
by the Medical Device branch of the Enterprise and Industry
Directorate-General of the European Commission.
    "The European Commission's workshop on vCJD diagnostic assays
demonstrates progress towards the establishment of European Union (EU)
regulations and the need for a viable vCJD blood screening test. We believe EU
technical standards will serve to validate the importance of vCJD blood
screening and encourage adoption among member states," said Dr. George Adams,
President & Chief Executive Officer of Amorfix. "We will attend as an industry
expert and a developer of in vitro diagnostic medical devices. The opportunity
to contribute to the regulatory process at this early stage is critical to
ensuring an appropriate and high standard for vCJD diagnostic assays."
    The attendees of the workshop will present and discuss the current state
of vCJD diagnostic development as well as the need to amend the current
products under the CTS framework to include vCJD diagnostic devices. The
workshop will also set up a subgroup to identify and recommend the necessary
technical data needed to amend the CTS and establish guidelines for
manufacturers and notified bodies. The vCJD workshop was scheduled under the
sponsorship of the United Kingdom.

    Common Technical Specifications

    Originally developed in 1998, the CTS framework is a directive of the
European Commission for EU-wide technical specifications for all regulated
products. The objective of CTS is to replace existing national rules of
individual members, which differ on a state by state basis, with one EU-wide
standard that applies to each member state. From time to time Directive
98/79/EC(1) is updated with new in vitro medical device products to ensure
conformity and a high level of health protection.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope Protection(TM)
(EP) technology enables it to specifically identify very low levels of
aggregated misfolded proteins (AMP) in a sample of normal protein. Aggregated
misfolded proteins are a common element of many brain wasting diseases and the
ability to identify AMPs and understand their structure and mechanism of
folding are the first steps to developing new treatments for these devastating
diseases. Amorfix's lead programs are a diagnostic blood screening test for
vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 482-3813, Fax: (416) 482-3811,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 482-3814, Fax: (416) 482-3811,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890